Oramed Pharmaceuticals Discloses 49.9% Stake in Lifeward Ltd. Following Strategic Acquisition and Financing

summarizeSummary

Oramed Pharmaceuticals Inc. has disclosed a 49.9% beneficial ownership stake in Lifeward Ltd., resulting from the acquisition of Oratech Pharma and a $9 million debt investment, marking a critical strategic shift for Lifeward.

check_boxKey Events

• Major Ownership Stake Disclosed

  Oramed Pharmaceuticals Inc. now beneficially owns 1,528,221 ordinary shares, representing 49.9% of Lifeward Ltd.'s outstanding shares.

• Strategic Acquisition Completed

  This ownership stems from Lifeward's acquisition of Oratech Pharma from Oramed, for which Oramed received 1,250,363 ordinary shares, pre-funded warrants for 1,006,113 shares, and share purchase warrants for 1,296,296 shares.

• Significant Debt Financing Provided

  Oramed also purchased $9 million in senior secured convertible notes from Lifeward, convertible at $5.40 per share, and received accompanying warrants for 1,666,666 shares.

• Beneficial Ownership Limitations

  All warrants and convertible notes are subject to beneficial ownership limitations, preventing Oramed from exceeding 49.99% (or 45% for notes/purchase warrants) of outstanding shares upon exercise/conversion.

auto_awesomeAnalysis

This Schedule 13D details Oramed Pharmaceuticals Inc.'s beneficial ownership of nearly 50% of Lifeward Ltd. following the acquisition of Oratech Pharma and a $9 million debt investment. This solidifies a major strategic partnership, providing Lifeward with a new business segment and crucial financing, especially significant given Lifeward's recent "going concern" warning. Oramed's substantial stake grants it significant influence over Lifeward's future direction and corporate strategy.